Point-counterpoint - Editor's comments

被引：0

作者：

Janzen, B ^{[1
]}

机构：

[1] Eli Lilly & Co, Sphinx Pharmaceut, Durham, NC 27705 USA

来源：

关键词：

D O I：

10.1177/108705719800300202

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

引用

页码：83 / 83

页数：1

共 50 条

[1] POINT-COUNTERPOINT
CASCIO, WF
[J]. SLOAN MANAGEMENT REVIEW, 1994, 35 (03): : 5 - 5
[2] POINT-COUNTERPOINT
EPSTEIN, WM
[J]. JOURNAL OF SOCIAL WORK EDUCATION, 1994, 30 (01) : 134 - 136
[3] Point-counterpoint
Fajardo, LL
[J]. ACADEMIC RADIOLOGY, 1996, 3 (05) : 442 - 443
[4] POINT-COUNTERPOINT
WALKER, CF
[J]. IEEE ENGINEERING IN MEDICINE AND BIOLOGY MAGAZINE, 1990, 9 (03): : 12 - 13
[5] Point-counterpoint
Wylie, Kevan R.
[J]. SEXUAL AND RELATIONSHIP THERAPY, 2010, 25 (03) : 258 - 258
[6] Point-counterpoint
Toth-Fejel, Tihamer T.
[J]. CHEMICAL & ENGINEERING NEWS, 2006, 84 (50) : 6 - 6
[7] Introduction to Point-Counterpoint
Blackham, Kristine A.
[J]. JOURNAL OF NEUROINTERVENTIONAL SURGERY, 2012, 4 (02) : 82 - 82
[8] COUNTERING POINT-COUNTERPOINT
BURKLE, DH
[J]. DRUG INTELLIGENCE & CLINICAL PHARMACY, 1978, 12 (01): : 56 - 56
[9] POINT-COUNTERPOINT - INTRODUCTION
SPECTOR, PE
[J]. JOURNAL OF ORGANIZATIONAL BEHAVIOR, 1995, 16 (03) : 199 - 199
[10] POINT-COUNTERPOINT - REPLY
LAFRANCO, M
TANNENBAUM, R
CANNON, M
[J]. DRUG INTELLIGENCE & CLINICAL PHARMACY, 1978, 12 (01): : 57 - 57